Plethora's PSD506 shows promise in OB and UUI
UK-based Plethora Solutions Holdings, a specialist developer of products for the management of urological disorders, says that preliminary data from a trial of PSD506 indicate that the drug has potential application in the treatment of overactive bladder or urge incontinence. Plethora is developing the drug under a license from Swiss drug major Roche (Marketletter October 2, 2006).
The dose escalation study indicates that PSD506, a novel muscarcinic receptor subtype selective antagonist, at dosages of 20mg or over provides effective relief from the condition. Plethora added that the agent had been well tolerated and the antimuscarinic dry-mouth side effects associated with other drugs of this class had not been observed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze